Story perspectives

Trump's Plan Aims to Lower Drug Prices and Boost Transparency

2/19/2026

Summary

Story summary

U.S. President Donald Trump’s administration aims to increase transparency in drug pricing as it regulates pharmacy benefit managers.
The proposed rules require PBMs to disclose compensation details and pass manufacturer rebates to health plans, addressing their control of nearly 80% of drug transactions.
A settlement against Express Scripts mandates ending the exclusion of cheaper insulin options.
The reforms are seen as a pivotal move to lower drug costs for Americans.

1 of 1

Story summary

U.S. President Donald Trump’s administration aims to increase transparency in drug pricing as it regulates pharmacy benefit managers.
The proposed rules require PBMs to disclose compensation details and pass manufacturer rebates to health plans, addressing their control of nearly 80% of drug transactions.
A settlement against Express Scripts mandates ending the exclusion of cheaper insulin options.
The reforms are seen as a pivotal move to lower drug costs for Americans.